Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/medecine/resistance-to-tyrosine-kinase-inhibitors/focosi/descriptif_3460046
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=3460046

Resistance to Tyrosine Kinase Inhibitors, Softcover reprint of the original 1st ed. 2016 Resistance to Targeted Anti-Cancer Therapeutics Series

Langue : Anglais

Coordonnateur : Focosi Daniele

Couverture de l’ouvrage Resistance to Tyrosine Kinase Inhibitors

The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.

Tyrosine Kinase Signaling Pathways in Normal and Cancer Cells.- Resistance to Tyrosine Kinase Inhibitors in different types of solid cancer.- The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview.- Resistance to FLT3 Inhibitors.- Resistance to ALK inhibitors.- Resistance to Angiokinase Inhibitors.- Indications for Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors.

Dr.Daniele Focosi was born in Lucca (Italy) in 1980. He graduated in Medicine with full grades in 2005 at the University of Pisa, and completed specialization in hematology in 2009. He achieved a Ph.D. degree in Clinical and Fundamental Virology in 2014, and a master degree in Clinical Trials in Oncology-Hematology in 2014.

He has authored 106 peer-reviewed manuscripts indexed on PubMed, for a total h-index of 16 and an overall impact factor of over 1400 points. He has been a fellow of the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste, and of the Collegio Ghislieri in Pavia, Italy. He is currently employed full-time at the Pisa University Hospital, where he is also a member of the Faculty of the PhD School in Clinical and Translational Sciences at University of Pisa.

He has given 37 oral and 47 poster presentations at international medical congresses, and is member of the editorial board of 17 peer-reviewed journals.

He has received awards from the European Federation of Immunogenetics, the European Society for Organ Transplantation, the Italian Society for Hematology, the Italian Interregional Transplant Association, the Italian Bone Marrow Donor Association, the Italian Society for Experimental Hematology, the Italian Society against Leukemia/Lymphoma/Myeloma.

The volume will provide readers with a primer on tyrosine kinase signaling and its importance in cancer

The reader will be first introduced to common denominators of small-molecule and antibody-derived inhibitors, and with the general phenomemon of resistance

Then specific reviews will focus on resistance to the most commonly used classes of tyrosine kinase inhibitors, namely BCR-ABL1, FLT3, the HER family members, angiokinase family members, ALK and the Raf/MEK/MAPK pathway

Includes supplementary material: sn.pub/extras

Date de parution :

Ouvrage de 188 p.

15.5x23.5 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

158,24 €

Ajouter au panier

Date de parution :

Ouvrage de 188 p.

15.5x23.5 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

158,24 €

Ajouter au panier